HomeCompareCRXTQ vs PLD

CRXTQ vs PLD: Dividend Comparison 2026

CRXTQ yields 142857.14% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRXTQ wins by $1.703105290929614e+28M in total portfolio value
10 years
CRXTQ
CRXTQ
● Live price
142857.14%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.703105290929614e+28M
Annual income
$17,007,633,297,048,937,000,000,000,000,000,000.00
Full CRXTQ calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — CRXTQ vs PLD

📍 CRXTQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRXTQPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRXTQ + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRXTQ pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRXTQ
Annual income on $10K today (after 15% tax)
$12,142,857.14/yr
After 10yr DRIP, annual income (after tax)
$14,456,488,302,491,595,000,000,000,000,000,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, CRXTQ beats the other by $14,456,488,302,491,595,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRXTQ + PLD for your $10,000?

CRXTQ: 50%PLD: 50%
100% PLD50/50100% CRXTQ
Portfolio after 10yr
$8.51552645464807e+27M
Annual income
$8,503,816,648,524,468,000,000,000,000,000,000.00/yr
Blended yield
99.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CRXTQ
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRXTQ buys
0
PLD buys
0
No recent congressional trades found for CRXTQ or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRXTQPLD
Forward yield142857.14%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$1.703105290929614e+28M$5.91M
Annual income after 10y$17,007,633,297,048,937,000,000,000,000,000,000.00$4,750,725.19
Total dividends collected$1.70295189426983e+28M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: CRXTQ vs PLD ($10,000, DRIP)

YearCRXTQ PortfolioCRXTQ Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$14,296,414$14,285,714.29$11,241$540.96+$14.29MCRXTQ
2$19,102,632,658$19,087,335,494.95$13,019$991.13+$19102.62MCRXTQ
3$23,856,124,353,624$23,835,684,536,679.88$15,801$1,870.97+$23856124.34MCRXTQ
4$27,845,102,711,212,050$27,819,576,658,153,670.00$20,609$3,701.21+$27845102711.19MCRXTQ
5$30,376,787,884,694,190,000$30,346,993,624,793,194,000.00$29,919$7,867.97+$30376787884694.16MCRXTQ
6$30,972,831,647,170,750,000,000$30,940,328,484,134,132,000,000.00$50,631$18,617.74+$30972831647170752.00MCRXTQ
7$29,516,720,240,819,920,000,000,000$29,483,579,310,957,454,000,000,000.00$105,528$51,352.20+$29516720240819920896.00MCRXTQ
8$26,290,911,335,300,946,000,000,000,000$26,259,328,444,643,270,000,000,000,000.00$287,364$174,449.42+$2.6290911335300947e+22MCRXTQ
9$21,887,488,081,496,375,000,000,000,000,000$21,859,356,806,367,600,000,000,000,000,000.00$1,081,760$774,280.77+$2.1887488081496375e+25MCRXTQ
10$17,031,052,909,296,140,000,000,000,000,000,000$17,007,633,297,048,937,000,000,000,000,000,000.00$5,908,209$4,750,725.19+$1.703105290929614e+28MCRXTQ

CRXTQ vs PLD: Complete Analysis 2026

CRXTQStock

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. On September 5, 2022, Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full CRXTQ Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CRXTQ vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRXTQ vs SCHDCRXTQ vs JEPICRXTQ vs OCRXTQ vs KOCRXTQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.